{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:30:15Z","timestamp":1791181815845,"version":"4.1.0"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The enzyme IMP dehydrogenase (IMPDH) catalyzes an essential step in the de novo biosynthesis of guanine nucleotides, namely, the conversion of IMP to XMP. The major event occurring in cells exposed to competitive IMPDH inhibitors such as ribavirin or uncompetitive inhibitors such as mycophenolic acid (MPA) is a depletion of the intracellular GTP and dGTP pools. Ribavirin is approved as an inhaled antiviral agent for treatment of respiratory syncytial virus (RSV) infection and orally, in combination with alpha interferon (IFN-\u03b1), for the treatment of chronic hepatitis C virus (HCV) infection. VX-497 is a potent, reversible uncompetitive IMPDH inhibitor which is structurally unrelated to other known IMPDH inhibitors. Studies were performed to compare VX-497 and ribavirin in terms of their cytotoxicities and their efficacies against a variety of viruses. They included DNA viruses (hepatitis B virus [HBV], human cytomegalovirus [HCMV], and herpes simplex virus type 1 [HSV-1]) and RNA viruses (respiratory syncytial virus [RSV], parainfluenza-3 virus, bovine viral diarrhea virus, Venezuelan equine encephalomyelitis virus [VEEV], dengue virus, yellow fever virus, coxsackie B3 virus, encephalomyocarditis virus [EMCV], and influenza A virus). VX-497 was 17- to 186-fold more potent than ribavirin against HBV, HCMV, RSV, HSV-1, parainfluenza-3 virus, EMCV, and VEEV infections in cultured cells. The therapeutic index of VX-497 was significantly better than that of ribavirin for HBV and HCMV (14- and 39-fold, respectively). Finally, the antiviral effect of VX-497 in combination with IFN-\u03b1 was compared to that of ribavirin with IFN-\u03b1 in the EMCV replication system. Both VX-497 and ribavirin demonstrated additivity when coapplied with IFN-\u03b1, with VX-497 again being the more potent in this combination. These data are supportive of the hypothesis that VX-497, like ribavirin, is a broad-spectrum antiviral agent.<\/jats:p>","DOI":"10.1128\/aac.44.4.859-866.2000","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"859-866","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":229,"title":["Broad-Spectrum Antiviral Activity of the IMP Dehydrogenase Inhibitor VX-497: a Comparison with Ribavirin and Demonstration of Antiviral Additivity with Alpha Interferon"],"prefix":"10.1128","volume":"44","author":[{"given":"W.","family":"Markland","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Vertex Pharmaceuticals Inc., Cambridge, Massachusetts 02139-4242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J.","family":"McQuaid","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Vertex Pharmaceuticals Inc., Cambridge, Massachusetts 02139-4242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jain","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Vertex Pharmaceuticals Inc., Cambridge, Massachusetts 02139-4242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Kwong","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Vertex Pharmaceuticals Inc., Cambridge, Massachusetts 02139-4242"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"207","article-title":"The role of de novo purine synthesis in lymphocyte transformation.","volume":"48","author":"Allison A. C.","year":"1977","unstructured":"Allison A. C. Hovi T. Watts R. W. E. Webster A. D. B. The role of de novo purine synthesis in lymphocyte transformation. Ciba Found. Symp. 48 1977 207 224","journal-title":"Ciba Found. Symp."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.11.2009"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1073\/pnas.96.7.3531","article-title":"Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design.","volume":"96","author":"Colby T. D.","year":"1999","unstructured":"Colby T. D. Vanderveen K. Strickler M. D. Markham G. D. Goldstein B. M. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc. Natl. Acad. Sci. USA 96 1999 3531 3536","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"De Clercq E. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact 1993 1 55 Academic Press Inc. New York N.Y","DOI":"10.1016\/S0065-3527(08)60082-2"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/rmv.1980050305","article-title":"Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpes viruses and retroviruses.","volume":"5","author":"De Clercq E.","year":"1995","unstructured":"De Clercq E. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpes viruses and retroviruses. Rev. Med. Virol. 5 1995 149 164","journal-title":"Rev. Med. Virol."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.4.679"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/11.5.1475"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.11.6.946"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.10.1668"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(97)00165-4"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.30.2.201"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/0006-291X(79)91853-9","article-title":"The broad spectrum antiviral agent ribavirin inhibits capping of mRNA.","volume":"89","author":"Goswami B. B.","year":"1979","unstructured":"Goswami B. B. Borek E. Sharma O. K. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89 1979 830 836","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"e_1_3_2_14_2","first-page":"118","article-title":"Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2\u2032,3\u2032-dideoxyadenosine and 2\u2032,3\u2032-dideoxyinosine.","volume":"40","author":"Hartman N. R.","year":"1991","unstructured":"Hartman N. R. Gurpreet S. A. Cooney D. A. Mitsuya H. Kageyama S. Fridland A. Broder S. Johns D. G. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2\u2032,3\u2032-dideoxyadenosine and 2\u2032,3\u2032-dideoxyinosine. Mol. Pharmacol. 40 1991 118 124","journal-title":"Mol. Pharmacol."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/07357909509094468","article-title":"The interferon system: a review with emphasis on the role of PKR in growth control.","volume":"13","author":"Jaramillo M. L.","year":"1995","unstructured":"Jaramillo M. L. Abraham N. Bell J. C. The interferon system: a review with emphasis on the role of PKR in growth control. Cancer Invest. 13 1995 327 338","journal-title":"Cancer Invest."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00007890-199808270-00016","article-title":"A randomized active-controlled trial of mycophenolate mofetil in heart transplants.","volume":"66","author":"Kobashigawa J.","year":"1998","unstructured":"Kobashigawa J. Miller L. Renlund D. Mentzer R. Alderman E. Bourge R. Costanzo M. Eisen H. Dureau G. Ratkovec R. Hummel M. Ipe D. Johnson J. Keogh A. Mamelok R. Mancini D. Smart F. Valantine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplants. Transplantation. 66 1998 507 515","journal-title":"Transplantation."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(92)90056-B"},{"key":"e_1_3_2_18_2","unstructured":"Kornberg A. Baker T. A. DNA replication 1992 53 100 W. H. Freeman & Co. New York N.Y"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.16.10807"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/095632029800900601","article-title":"Treatment of chronic viral hepatitis.","volume":"9","author":"Main J.","year":"1998","unstructured":"Main J. McCarron B. Thomas H. C. Treatment of chronic viral hepatitis. Antivir. Chem. Chemother. 9 1998 449 460","journal-title":"Antivir. Chem. Chemother."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.2.216"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.4049\/jimmunol.160.7.3487","article-title":"Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response.","volume":"22","author":"Ning Q.","year":"1998","unstructured":"Ning Q. Brown D. Parodo J. Cattral M. Gorczynski R. Cole E. Fung L. Ding J. W. Liu M. F. Rotstein O. Phillips M. J. Levy G. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J. Immunol. 22 1998 3487 3493","journal-title":"J. Immunol."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug-drug interactions.","volume":"14","author":"Prichard M. N.","year":"1992","unstructured":"Prichard M. N. Shipman C. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14 1992 181 206","journal-title":"Antivir. Res."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0042-6822(89)90413-3","article-title":"Studies on the mechanism of the antiviral activity of ribavirin against reovirus.","volume":"168","author":"Rankin J. T.","year":"1989","unstructured":"Rankin J. T. Eppes S. B. Antczak J. B. Joklik W. K. Studies on the mechanism of the antiviral activity of ribavirin against reovirus. Virology 168 1989 147 158","journal-title":"Virology"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(91)90881-B"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of virazole: 1-\u03b2-d-ribofranosyl-1,2,4-triazole-3-carboxamide.","volume":"177","author":"Sidwell R. W.","year":"1972","unstructured":"Sidwell R. W. Huffman J. H. Khare G. P. Allen L. B. Witkowski J. T. Robins R. K. Broad-spectrum antiviral activity of virazole: 1-\u03b2-d-ribofranosyl-1,2,4-triazole-3-carboxamide. Science 177 1972 705 706","journal-title":"Science"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0190-9622(97)70147-6","article-title":"Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses.","volume":"37","author":"Silverman Kitchin J. E.","year":"1997","unstructured":"Silverman Kitchin J. E. Keltz Pomeranz M. Pak G. Washenik K. Shupack J. L. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J. Am. Acad. Dermatol. 37 1997 445 449","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81275-1"},{"key":"e_1_3_2_29_2","first-page":"A56","article-title":"X-ray crystal structure of the antiviral drug ribavirin monophosphate bound to IMP dehydrogenase.","volume":"41","author":"Sintchak M. D.","year":"1999","unstructured":"Sintchak M. D. Badia M. C. Futer O. Nimmesgern E. X-ray crystal structure of the antiviral drug ribavirin monophosphate bound to IMP dehydrogenase. Antivir. Res. 41 1999 A56","journal-title":"Antivir. Res."},{"key":"e_1_3_2_30_2","first-page":"A52","article-title":"Mode of action of ribavirin against cowpox and monkeypox viruses.","volume":"41","author":"Smee D. F.","year":"1999","unstructured":"Smee D. F. Huggins J. W. Mode of action of ribavirin against cowpox and monkeypox viruses. Antivir. Res. 41 1999 A52","journal-title":"Antivir. Res."},{"key":"e_1_3_2_31_2","first-page":"24","article-title":"Update on preclinical and clinical experience with mycophenolate mofetil.","volume":"28","author":"Sollinger H. W.","year":"1995","unstructured":"Sollinger H. W. Update on preclinical and clinical experience with mycophenolate mofetil. Transplant. Proc. 28 1995 24 29","journal-title":"Transplant. Proc."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(99)80093-2","article-title":"Ribavirin polarizes human T cell responses towards a type 1 cytokine profile.","volume":"30","author":"Tam R. C.","year":"1999","unstructured":"Tam R. C. Pai B. Bard J. Lim C. Averett D. R. Phan U. T. Milovanovic T. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J. Hepatol. 30 1999 376 382","journal-title":"J. Hepatol."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.4.492"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0168-8278(98)80133-5","article-title":"Combination therapy of chronic hepatitis C: an important step but not the final goal!","volume":"29","author":"Wedemeyer H.","year":"1998","unstructured":"Wedemeyer H. Caselmann W. H. Manns M. P. Combination therapy of chronic hepatitis C: an important step but not the final goal! J. Hepatol. 29 1998 1010 1014","journal-title":"J. Hepatol."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0166-3542(85)90013-0","article-title":"Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro.","volume":"5","author":"Wray S. K.","year":"1985","unstructured":"Wray S. K. Gilbert B. E. Knight V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antivir. Res. 5 1985 39 48","journal-title":"Antivir. Res."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(85)90012-9"},{"key":"e_1_3_2_37_2","first-page":"122A","article-title":"Dose-ranging study of VX-497, a novel, oral IMPDH inhibitor, in patients with hepatitis C.","volume":"30","author":"Wright T.","year":"1999","unstructured":"Wright T. Shiffman M. L. Knox S. Ette E. Kauffman R. S. Alam J. Dose-ranging study of VX-497, a novel, oral IMPDH inhibitor, in patients with hepatitis C. Hepatology 30 (Suppl.) 1999 122A","journal-title":"Hepatology"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF02171743","article-title":"Mycophenolate mofetil: molecular mechanisms of action.","volume":"2","author":"Wu J. C.","year":"1994","unstructured":"Wu J. C. Mycophenolate mofetil: molecular mechanisms of action. Perspect. Drug Disc. Design 2 1994 185 204","journal-title":"Perspect. Drug Disc. Design"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.4.859-866.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.4.859-866.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T15:49:54Z","timestamp":1682264994000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.4.859-866.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,4]]}},"alternative-id":["10.1128\/AAC.44.4.859-866.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.4.859-866.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,4]]},"assertion":[{"value":"1999-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-01-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}